- HM Sampoerna‘s net income for the first half of 2024 is 3.32 trillion rupiah.
- This net income represents a 12% decrease compared to the same period last year.
- Total revenue for the first half of 2024 is 57.82 trillion rupiah, showing a 3% increase year-over-year.
- Earnings per share (EPS) are 29 rupiah, down from 32 rupiah in the previous year.
- Analyst recommendations include 14 buys, 3 holds, and 3 sells.
- All comparisons are based on values reported in the company’s original disclosures.
A look at HM Sampoerna Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
PT Hanjaya Mandala Sampoerna Tbk, a company known for manufacturing clove-blended cigarettes, seems to have a positive long-term outlook based on Smartkarma Smart Scores. With a strong score of 5 in Dividend and Resilience, Sampoerna is recognized for its ability to provide consistent dividend payouts and withstand market challenges effectively. Additionally, a Growth score of 3 indicates moderate potential for expansion, while Momentum at 3 suggests a stable trajectory in the near future.
The company’s overall outlook, as indicated by the combination of these scores, appears promising. Sampoerna’s focus on dividends and resilience, coupled with opportunities for growth and a steady momentum, positions it well for the future. As a manufacturer of clove-blended cigarettes with a presence in both domestic and international markets, Sampoerna’s diversified operations and strong financial standing contribute to its positive Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
